Wedbush raised the firm’s price target on AnaptysBio (ANAB) to $45 from $40 and keeps an Outperform rating on the shares after the company reported earnings, confirmed stock buybacks, and disclosed celiac disease as the lead indication for CD122 antagonist mAb ANB033. A remaining $19.5MM is available for stock buybacks, which the firm expects the company to achieve this quarter.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- Promising Clinical Trial Results and Strategic Growth Potential Drive Buy Rating for AnaptysBio
- AnaptysBio Reports Q2 2025 Financial Results and Updates
- AnaptysBio: Promising Pipeline and Strategic Developments Justify Buy Rating
- AnaptysBio reports Q2 EPS ($1.34), consensus ($1.58)
- AnaptysBio Faces Critical Risk: Potential Impact on Operations and Investor Confidence